A virosome is an innovative hybrid drug delivery system with advantages of both viral and non-viral vectors. Studies have shown that a virosome can carry various biologically active molecules, such as nucleic acids, peptides, proteins and small organic molecules. Targeted drug delivery using virosome-based systems can be achieved through surface modifi cations of virosomes. A number of virosome--based prophylactic and therapeutic products with high safety profi les are currently available in the market. Cancer treatment is a big ba lefi eld for virosome-based drug delivery systems. This review provides an overview of the general concept, preparation procedures, working mechanisms, preclinical studies and clinical applications of virosomes in cancer treatment.
utilize their advantages, a virosome, a hybrid drug delivery system composed of both viral and non-viral components, was invented.
First prepared by Almeida et al. (10) (11) (12) (13) , a virosome is composed of a phospholipid bilayer with viral surface glycoproteins protruding from it. Inside a virosome, there is often a cavity that can be utilized to carry organic compounds, nucleic acids or proteins to the target sites (Fig. 1) . By mimicking a natural viral infection, virosomes can recognize and bind to specifi c receptors to enter the target cells; they are therefore very effi cient in drug delivery. In addition, since they lack genetic materials of parent viruses, virosomes are generally safe in usage. To date, infl uenza viruses, hemagglutinating virus of Japan (HVJ or Sendai virus) and several other viruses have been successfully reconstituted to produce virosomes (14) (15) (16) (17) (18) (19) (20) (21) .
COMMONLY USED VIROSOMES

Virosomes reconstituted from infl uenza viruses
Virosomes reconstituted from infl uenza viruses may be the most frequently used ones. The envelope of these virosomes is composed of a phospholipid bilayer; meanwhile, viral glycoproteins, hemagglutinin (HA) and neuraminidase (NA) are frequently displayed on the surface of the virosome. HA is the receptor-binding and membrane fusion protein of infl uenza; it can form homotrimers and changes its conformations at acidic pH to become fusion-competent (22) (23) (24) . The other glycoprotein NA does not only enhance the entry of viruses into cells (25) but also facilitates release of progeny viruses at the budding stage by removing terminal sialic acid from saccharide chains on the host cell surface (26) .
Virosomes reconstituted from hemagglutinating virus of Japan
Due to its highly effi cient delivery of nucleic acids, proteins and biologically active macromolecules, the HVJ-derived virosomes are especially promising. These virosomes use hemagglutinating (HN) protein and fusion (F) protein for cell fusion (Fig. 2) . HN protein can bind to acetyl-type sialic acid at the host cell surface and the F protein associates with lipids, such as cholesterol, to induce membrane fusion of the virosome and host cells (27) . Electron microscope-based analysis can be used to determine the size and structure of virosomes. The ultimate sizes of virosomes are usually determined by the nature of the viral protein and the composition of the phospholipid bilayer. HVJ virosomes have a mean diameter of 400-500 nm, while infl uenza virosomes are generally 150-200 nm in diameter (33) . The size of virosomes is one of the most important factors aff ecting the interaction between particular virosomes and their target cells (34) . Fig. 2 . The working mechanism of a HVJ-derived virosome. The envelope of HVJ-based virosome is composed of a phospholipid bilayer which has fusion proteins (F, square) and hemagglutinating protein (HN protein, cylinder) displayed on the surface of the virosomes. Drug molecules (such as organic compounds, proteins, peptides, siRNAs, plasmid DNAs) are fi rst incorporated into these virosomes, then the whole virosome molecules will bind to the receptors and fuse with host membrane through membrane fusion. The incorporated drug molecules are then delivered intracellularly.
Administration of virosomes
Prepared virosomes are o en suspended in saline buff ers (135-150 mmol L -1 NaCl), which o en contain other auxiliary elements (such as calcium chloride, potassium chloride, sodium acetate, sodium lactate) to mimic physiological conditions (35) . The concentrations of virosomes are o en in the range between 20 and 200 mg mL -1 in their buff ers, depending upon the properties of virosome components and particular purposes (29) . The formulated virosomes are usually sterilized (for example, through membrane fi ltration) before they are administrated through parenteral, intravenous, oral, intramuscular, topical or respiratory routes (36) (37) (38) .
Optimization of virosomes
Hydrophilic polymers [such as polyethylene glycol, polyacryloylmorpholine, polyvinylpyrrolidone and poly(2-oxazoline)] can be inserted into the envelope of virosomes to elongate their circulation time a er systemic delivery (39) . More importantly, to achieve a target selecting ability, targeting molecules (such as antibodies) can be conjugated to these hydrophilic polymers and inserted into the membrane of virosomes (40, 41) .
Application of virosomes as drug delivery systems
Virosomal systems have been used to deliver almost all forms of drugs, such as organic molecules, proteins, peptides and nucleic acids. The lipid bilayer of virosomes serves to protect these therapeutic materials from degradation by host defense systems (42) . De Jonge et al. (43) successfully encapsulated plasmid DNA in reconstituted infl uenza virosomes, which completely protected the transferring DNA from degradation by nucleases and helped the transfection effi ciency to achieve about 90 %. Similarly, siRNA can be delivered by virosomes to inhibit the expression of target genes in vitro and in vivo. In order to increase the loading of siRNA into virosomes, cationic lipids such as N,N-dioleoyl-N,Ndimethylammonium chloride can be used (44) . The delivery effi ciency of infl uenza virosomes is comparable to that when using a commercial liposome such as Lipofectamine ® 2000; however, the toxicity of infl uenza virosomes is much lower than that of Lipofectamine ® 2000. In addition, virosomes can also be used to deliver proteins and peptides. For example, the gelonin subunit A of diphtheria toxin has been delivered to target cells by virosomes, as well as ovalbumin (45) (46) (47) . Strong cytotoxic T lymphocyte responses can be induced by peptides derived from the infl uenza nucleoprotein delivered by virosomes. All evidence indicated that the encapsulated peptides and proteins gained access to the cytoplasm (48, 49) .
Advantages and disadvantages of virosomal drug delivery systems
The unique characteristics of virosome membranes provide them with features of being biocompatible and biodegradable (35) . Once inside the cells, virosomes cannot replicate, ensuring their safety profi le. Another merit of virosomes is that they can be broadly applied with almost all forms of drugs, such as small organic molecules, proteins, peptides and nucleic acids.
Comparison with liposomes
Liposomes have been considered to be among the most potent vehicles for delivering bioactive molecules both in vitro and in vivo. However, due to the low effi ciency of liposomes to fuse with cells, they o en do not effi ciently deliver encapsulated molecules to the cells. In contrast, virosomes usually guarantee cellular delivery of encapsulated molecules since they contain viral envelope glycoproteins with receptor-binding and membrane --fusion properties (50). Nakamura et al. (51) have shown that oligonucleotides can be intracellularly delivered with up to three times greater effi ciency by HVJ-virosomes compared to cationic liposomes.
Another major problem associated with liposomes is their rapid clearance by the body's reticuloendothelial system (52) . In contrast, virosomes can deliver bioactive agents to the target cells without being aff ected by the host defense mechanisms for a period of time. Virosomes o en excellently preserve the stability and activity of encapsulated therapeutic agents until the drug molecules are intracellularly delivered (53, 54) .
Targeted drug delivery by virosomes
The distribution of drugs in diff erent parts of the body is always an important issue for pharmaceutical scientists. So far, tumor cells, erythrocytes, hepatocytes and cells of the respiratory and gastrointestinal systems have been successfully targeted by virosomes (55, 56) . One can tailor virosomes to specifi c targets by incorporating various ligands such as cytokines, peptides, and monoclonal antibodies on the surface of virosomes (57) .
Disadvantages of virosomal drug delivery systems
Like any other technique, also virosome-based delivery systems have their own disadvantages. One disadvantage is that virosomes might induce immune responses because they o en have viral glycoproteins on the surface (11, 58) . On the other hand, the feature of inducing prophylactic responses can help in establishing virosomes as vaccine and immunological adjuvants. Rapid disintegration in the blood compartment could be another potential issue associated with virosomes. This issue can be overcome by increasing the stability of virosomes or by making virosomes reach targeting sites within a short time a er administration.
CLINICAL AND PRECLINICAL APPLICATIONS OF VIROSOMES IN CANCER TREATMENT
Several virosome-based agents with high safety profi les have been approved by the United States Food and Drug Administration (FDA) for use in humans (59) . So far, virosomes have successfully delivered anti-cancer, anti-malarial, anti-bacterial, and anti-fungal agents in vitro and in vivo (60) (61) (62) (63) (64) . However, because of our research interests, in the current review, we will mostly focus on the application of virosomes in cancer treatment.
Virosomes as an adjuvant delivery system for cancer vaccines
Cancer immunotherapy represents a new class of cancer treatment which harnesses and enhances the innate activities of the immune system to combat tumors and is increasingly accepted as a treatment option for advanced stages of cancers. This idea is so a rac-tive that Science editors have chosen cancer immunotherapy as one of the Top10 Breakthroughs of 2013. Recent studies have shown that virosomes can be an ideal antigen delivery system for cancer treatment.
Virosomes are ideal vehicles for delivering immunogenic substances in host bodies due to their two reciprocally reinforcing functions when used as vaccines. On one hand, virosomes are good vehicles for transferring the immunogen into the body; on the other hand, they are highly eff ective as immune adjuvants since their surface viral glycoproteins can stimulate humoral responses in their native conformation (35, 65) . Once the virosomebased vaccines have been administered, both the cellular and humoral arms of the host immune systems are effi ciently activated (66, 67) . Therefore, virosome-based vaccines are very effi cient in arousing immunity responses. It has been reported that two doses of Epaxal, a virosome-based vaccine, administered 12 months apart, off ered adults a protection of at least 9 to 11 years (68).
Virosome-formulated vaccines had been used in several preclinical studies and clinical trials for cancer treatment (48, (69) (70) (71) (72) . For example, Schwaninger et al. (73) immunized mice with the truncated protein pNeuECD carried by virosomes. Their results showed that the vaccinated mice generated Neu-specifi c humoral and cytotoxic immune responses. Furthermore, virosome-carried pNeuECD resulted in signifi cant tumor rejection when compared free pNeuECD in complete Freund's adjuvant.
Cervical cancer is one of the cancers that has been successfully treated by immunotherapy of virosome-formulated vaccines. Virosome-fomulated cervical cancer vaccines have been actively studied recently (74, 75) . In a murine model system, a vigorous class I MHC-restricted cytotoxic T-lymphocyte (CTL) response against HPV-transformed tumor cells was established by using fusion-active infl uenza virosomes which contained recombinant human papillomavirus type 16 (HPV16) E7 protein antigen. E7-specifi c antibody responses were also induced in this study. Conjunction of humoral and cytotoxic immune responses successfully prevented tumor outgrowth in more than 70 % of the animals immunized with E7-containing virosomes. Therefore, this study suggested that the infl uenza--derived virosomes containing E7 protein represent a promising immunotherapeutic vaccine for the treatment of cervical cancer (74) . Walczak et al. (75) also found that virosomes containing the HPV16 E7 protein resulted in high numbers of antigen-specifi c cytotoxic T lymphocytes (CTL) in mice.
Adamina et al. (76) have already started the tailoring of dedicated advanced liposomal and virosome vectors for the immunotherapy of melanoma due to its recognition as an immunogenic tumor and an unprecedented rise in the incidence of melanoma. Schumacher et al. (77) formulated immunopotentiating reconstituted infl uenza virosomes (IRIV) to effi ciently encapsulate L(27)Melan-A/ Mart-1 (26-35) HLA -A0201 restricted peptide, a melanoma-associated antigen widely used in tumor immunotherapy. They found that this reagent signifi cantly enhanced the generation of L(27)Melan-A/Mart-1(26-35) specifi c CTL compared to soluble peptides, in particular at low nominal epitope concentrations (< 1 µg mL -1 ). This highly immunogenic antigenic formulation was suggested for further clinical evaluations of melanoma immunotherapy.
Virosomes as carriers for other bioactive molecules in cancer treatment
Besides tumor antigens, other bioactive molecules, such as oligonucleotides and small organic compounds that can exert anti-tumor activities may also be delivered by viro-somes. Zakaria et al. (78) used Sendai virosomes (which are hepatocytes-specifi c due to their F protein on the surface) to deliver shRNA against oncogene c-Myc in hepatocarcinoma cells. Their approach induced specifi c heterochromatization and increased DNA methylation of the CpG islands around the target loci of shRNA, which ultimately resulted in apoptosis of the targeted hepatocarcinoma cells.
More importantly, virosomes can deliver drugs specifi cally to the target cancer cells by displaying appropriate molecules (such as antibodies or affi bodies) on their surface (65) . Recently, cancer cell-specifi c siRNAs have been delivered using a modifi ed virosome system on which affi body molecules of HER2 (human epidermal growth factor receptor 2, o en expressed on breast and ovarian cells) were displayed (79) . Magnetic force can also be used to drive virosome-formulated anti-cancer medicines into tumor tissues (80) . A novel formulation of Decitabine, based on the use of the erythro-magneto-hemagglutinin virosomes (EMHVs) drug delivery system has been refi ned by Cinti's team (63) . Their EMHV delivery system improved pharmacokinetics/pharmacodynamics of Decitabine, specifi cally transported the drugs into tumor tissues, and fi nally induced a signifi cant tumor mass reduction in xenogra models of prostate cancer at a concentration much lower than its therapeutic dose in free form.
Virosomes themselves as anti-cancer reagents
Surprisingly, recent studies have shown that virosomes may have anti-tumor activities just by themselves. Kurooka et al. (81) have demonstrated that direct injection of the HVJ envelope into murine colon carcinoma (CT26) tumors growing in syngeneic BALB/c mice can eradicate 60 to 80 % of the tumors by both production of tumor-specifi c cytotoxic T cells and blocking of regulatory T cell activity. HVJ-E injection has also been shown to inhibit Renca tumor growth by enhancing local CXCL10 expression and systemic NK cell activation (82) . In addition, two studies have shown that HVJ-E vector directly killed human prostate cancer cells and glioblastoma cells in vitro and in vivo by inducing apoptosis in tumor cells through activation of interferon-related pathways (83, 84) . Overall, the anti-tumor benefi ts of the HVJ envelope may come from induced anti-tumor immune responses and induced apoptosis in tumor cells.
FUTURE PROSPECTS
As a novel and eff ective drug-delivery system, virosomes are used for delivering a broad range of biologically active molecules. Many virosome-based, prophylactic and therapeutic products, especially vaccines, have been approved by administration authorities in diff erent countries and are currently available in the market. However, the comprehensive pharmacological profi les and stability of virosomes should be studied thoroughly to verify their long-term reliability as a safe, effi cient, and economical way of drug delivery. Moreover, the complicated assay processes for characterizing virosome products hold back the development of virosomes. Eff orts, therefore, need to be made in this respect to speed up the development of virosome-based products. In conclusion, virosome-based biopharmaceuticals have a high potential for rapid translation into the clinic with improvements and further tests, especially in the area of cancer treatment.
